About these ads

Retraction Watch

Tracking retractions as a window into the scientific process

Archive for the ‘cardiology retractions’ Category

If only more retractions could be like this: Authors of cardiac stem cell paper show the way

with 5 comments

Researchers at Qingdao University have fully retracted a paper originally published in Molecular Medicine Reports with a clear, detailed outline of what went wrong and how they discovered the error.

Here’s the notice for “Generation of induced pluripotent stem cells using skin fibroblasts from patients with myocardial infarction under feeder-free conditions:”

Read the rest of this entry »

About these ads

Author squabble sinks cardiology papers

with one comment

Two papers on “novel techniques” have been retracted with what is unfortunately a very non-novel technique: an odd notice and silence when we asked for comment.

Here’s the explanation for retraction of “A novel approach to treat residual peridevice leakage after left-atrial appendage closure,” by Wunderlich N, Wilson N, and Sievert H: Read the rest of this entry »

Ninth retraction appears for cardiology researcher Matsubara

with 3 comments

matsubaraHiroaki Matsubara, a former Kyoto Prefectural University cardiology researcher who resigned last year following an investigation, has had another paper retracted, his ninth.

Here’s the notice from Arteriosclerosis, Thrombosis, and Vascular Biology: Read the rest of this entry »

BMJ authors take back inaccurate statin safety statements

with 9 comments

bmjcover514Last October, the BMJ published a paper by a group of researchers from the United States and Canada questioning the use of statins in patients considered at low risk of cardiovascular disease.

The article has been cited eight times since then, according to Thomson Scientific’s Web of Knowledge. It mentioned data from another study that reported a high rate of side effects in patients who used the drugs, between 18% and 20% — suggesting that those who received little or no benefit from the therapy could be more more likely to suffer harm than good.

But that citation turns out to have been flawed — prompting the journal to take the unusual step of removing those “statements” from the article and another it published about the issue that has been cited six times. And in an editorial, BMJ editor Fiona Godlee said she has asked a panel of experts to review the original paper to determine if it ought to be retracted completely: Read the rest of this entry »

Written by amarcus41

May 14, 2014 at 7:01 pm

Heart study retracted because it was submitted without permission of most of the authors

with 4 comments

clincardcoverA group of authors in South Korea has lost their 2012 paper in Clinical Cardiology because, well, they weren’t a group after all.

The paper, “Correlation of Electrocardiographic Changes and Myocardial Fibrosis in Patients With Hypertrophic Cardiomyopathy Detected by Cardiac Magnetic Resonance Imaging,” came from corresponding author of Konkuk University School of Medicine in Seoul, and a half-dozen colleagues. At least, that’s what the manuscript said.

But according to the retraction notice, Yang had nothing to do with the paper — nor did five other co-authors. Read the rest of this entry »

Harvard-Brigham heart researcher under investigation earns Lancet Expression of Concern

with 7 comments

logo_lancetOn Tuesday, we broke the news of the retraction in Circulation of a paper on cardiac stem cells by a group of researchers being investigated by Harvard Medical School and the Brigham and Women’s Hospital. Today, The Lancet has issued an Expression of Concern about another paper led by Piero Anversa, the last author of the Circulation paper.

Read the rest of this entry »

Written by Ivan Oransky

April 11, 2014 at 6:44 am

Harvard and the Brigham investigating leading heart group for “compromised” data

with 35 comments

circulationcoverCirculation has retracted a 2012 study by a group of Harvard heart specialists over concerns of corrupt data, and the university is investigating. The group was led by Piero Anversa, a leading cardiologist, and Joseph Loscalzo — who will be familiar to readers of Circulation as the editor in chief of that journal. (Anversa’s also on the editorial board).

Read the rest of this entry »

Do you see what I see? Heart imaging journal yanks cardiac study for plagiarism

with one comment

intjcardimagThe International Journal of Cardiovascular Imaging has retracted a 2013 paper by a group of researchers from Italy. The reason: plagiarism.

The paper was titled “Diagnostic accuracy of 320-row computed tomography as compared with invasive coronary angiography in unselected, consecutive patients with suspected coronary artery disease,” and it came from scientists in Rome led by Francesco Pelliccia of the Department of Heart and Great Vessels at Sapienza University.

Read the rest of this entry »

Written by amarcus41

April 4, 2014 at 11:00 am

Late resveratrol researcher Dipak Das manages to revise and publish paper from the grave

with 15 comments

Das, via UConn

Das, via UConn

Follow this timeline, if you would:

  • August 14, 2013: Former UConn researcher Dipak Das, who was found to have committed misconduct, submits a paper to Oxidative Medicine and Cellular Longevity.
  • September 19, 2013: Das dies.
  • October 17, 2013: Das submits revisions to his paper in Oxidative Medicine and Cellular Longevity.
  • October 18, 2013: Paper accepted.
  • January 12, 2014: Paper published.

That would appear to be what the timeline on the paper — which lists Das as corresponding author, along with a Gmail address — says:

Read the rest of this entry »

Written by Ivan Oransky

April 3, 2014 at 10:00 am

Novartis Diovan scandal claims two more papers

with 6 comments

diabetes careA complicated story involving Novartis’s valsartan (Diovan) has led to the retraction of two more papers, one cascading from the other.

Last September, The Lancet retracted the Jikei Heart Study after a slew of retractions of related work prompted an investigation of valsartan research. That investigation found evidence of data manipulation and the failure of one researcher to note his Novartis affiliation. The company has apologized.

Here’s one retraction, from Diabetes Care, for “The Shiga Microalbuminuria Reduction Trial (SMART) Group. Reduction of Microalbuminuria in Patients With Type 2 Diabetes: The Shiga Microalbuminuria Reduction Trial (SMART):”

Read the rest of this entry »

Follow

Get every new post delivered to your Inbox.

Join 33,722 other followers